-
-
CPDM has a team of in vitro/in vivo technicians, bioinformaticians, and scientists offering a wide range of potential collaborations for specific novel method development around cancer modeling or model characterization, including novel assay
development.
CPDM welcomes partnering with academia and industry collaborators on method and technology evaluation; we can use cancer models and their associated rich clinical annotations to help validate the application of novel technologies prior to deployment.
Please email us at models@dfci.harvard.edu to explore collaboration ideas.